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Immunoglobulin A (IgA) nephropathy is the most prevalent
form of glomerulonephritis worldwide. A renal biopsy is
required for an accurate diagnosis, as no convenient
biomarker is currently available. We developed a serological
test based upon the observation that this nephropathy is
characterized by undergalactosylated IgA1 in the circulation
and in mesangial immune deposits. In the absence of
galactose, the terminal saccharide of O-linked chains in the
hinge region of IgA1 is terminal or sialylated
N-acetylgalactosamine. A lectin from Helix aspersa,
recognizing N-acetylgalactosamine, was used to develop an
enzyme-linked immunosorbent assay that measures
galactose-deficient IgA1 in serum. The median serum
lectin-binding IgA1 level was significantly higher for 153
Caucasian adult patients with IgA nephropathy without
progression to end-stage renal disease as compared with
that for 150 healthy Caucasian adult controls. As the
lectin-binding IgA1 levels for the controls were not normally
distributed, the 90th percentile was used for determination
of significant elevation. Using a value of 1076 U/ml as the
upper limit of normal, 117 of the 153 patients with IgA
nephropathy had an elevated serum lectin-binding IgA1
level. The sensitivity as a diagnostic test was 76.5%, with
specificity 94%; the positive predictive value was 88.6% and
the negative predictive value was 78.9%. We conclude that
this lectin-binding assay may have potential as a
noninvasive diagnostic test for IgA nephropathy.
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Since its initial description in 1968,1 immunoglobulin A
(IgA) nephropathy (IgAN) has become recognized as the
most common primary glomerulonephritis worldwide.2
IgAN is characterized by mesangial deposits of IgA1 with
co-deposits of C3, and often also IgG or IgM or both.1,3–6
Over 50% of IgAN patients exhibit increased serum levels of
IgA and IgA-containing circulating immune complexes
(CIC).7–9 The mesangial immune deposits likely originate
from these CIC. We have found that these complexes contain
aberrantly glycosylated polymeric IgA1 (galactose (Gal)-
deficient in O-linked glycans).10–13 In vitro studies have
demonstrated that these CIC readily bind to mesangial cells
and induce their proliferation.12–16 Thus, aberrantly glyco-
sylated polymeric IgA1 may be involved in the pathogenesis
of the glomerular injury in IgAN. Indeed, elution of
glomerular immune deposits from renal tissue of patients
with IgAN has demonstrated substantial quantities of Gal-
deficient IgA1.17,18
Several laboratories have localized the aberrant glycosyla-
tion to the O-linked glycans in the hinge region of some IgA1
molecules.5,15,19–21 In the absence of Gal, the terminal N-
acetylgalactosamine (GalNAc) residues, sialylated GalNAc, or
the hinge-region glycopeptides are recognized by naturally
occurring IgG or IgA1 antibodies with anti-glycan or anti-
hinge region peptide specificities, thus generating CIC.10
Some of the resultant CIC escape normal clearance and
deposit in the mesangium. These observations support the
postulate that O-glycosylation abnormalities of IgA1 predis-
pose to mesangial IgA deposition.5,12,14,15,21,22
For the diagnosis of IgAN, a renal biopsy is required
because there is no established serological marker. To avoid
this invasive procedure, particularly in individuals with mild
disease, we sought to develop a noninvasive test to support
the diagnosis of IgAN using a GalNAc-specific lectin. Based
on previous work by our group and others, the lectin from
Helix aspersa (HAA) is well suited for detecting Gal-deficient
IgA1 O-linked glycans.10,11,15–17,23–26 In this study, we show
that a quantitative lectin-based enzyme-linked immunosor-
bent assay (ELISA) can be successfully used to measure serum
levels of Gal-deficient IgA in sera of patients with IgAN.
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RESULTS
Serum IgA concentration
Median serum IgA concentration was 3 943 mg/ml (range
1 171–11 713 mg/ml) for 153 Caucasian IgAN patients who
had not progressed to end-stage renal disease as compared
with 2 843 mg/ml (range 886–8 185 mg/ml) for 150 healthy
controls (Po0.0001) (Table 1). Fifty patients had a serum
IgA concentration higher than 4 761 mg/ml (90th percentile
for controls). These data indicate a sensitivity of 32.7% and
specificity of 90% with a positive predictive value of 76.9%
and a negative predictive value of 56.7% (Table 2). In
agreement with a previous publication,22 the diagnostic
utility of total levels of serum IgA was not satisfactory.
Serum HAA-IgA levels
Serum HAA-IgA levels for the patient and healthy control
groups are shown in Figure 1a. The individual levels for the
control group were not distributed normally with a marked
skewing towards elevated levels. The median serum HAA-IgA
level for the patients of 1 731 U/ml (range 320–8 317 U/ml)
was significantly higher than the median of 615 U/ml (range
264–1 807 U/ml) for the control group (Po0.0001). The
serum HAA-IgA level was higher than 1 076 U/ml (90th
percentile for controls) for 117 of the 153 patients. These data
indicate a sensitivity of 76.5% and a specificity of 90% with a
positive predictive value of 88.6% and a negative predictive
value of 78.9%. To illustrate the potential of this assay, the
results are also presented as a receiver operating characteristic
curve in Figure 1b. The area under the curve is 0.9021 with a
standard error 0.0178, indicating that the true-positive rate
was high and the false-positive rate was low. The 95%
confidence interval was 0.8672–0.9370 (Po0.0001).
Reproducibility of the HAA-IgA ELISA was high (repeated the
assays had an r¼ 0.970; Po0.0001). The serum HAA-IgA and
IgA levels correlated significantly in IgAN patients (r2¼ 0.571,
Po0.0001) and healthy controls (r2¼ 0.392, Po0.0001).
The median value of the HAA-binding fraction of IgA was
445 U/mg IgA (range 129–879) for 153 Caucasian IgAN
patients who had not progressed to end-stage renal disease as
compared with 248 U/mg IgA (range 56–666) for 150 healthy
controls (Po0.0001). Ninety-four patients had a HAA-
binding fraction of IgA higher than 394 U/mg IgA (90th
percentile for controls). These data indicate a sensitivity of
61.4% and specificity of 90% with a positive predictive value
of 86.2% and a negative predictive value of 69.6%. Seven of
36 patients with normal HAA-IgA levels had an HAA-
binding fraction of IgA above the 90th percentile for controls;
among the 135 healthy controls with a HAA-IgA level below
Table 1 | Clinical features and levels of serum IgA and HAA-IgA for subgroups of patients with IgA nephropathy
Group N
Gender
ratio
(M/F)
Age at
diagnosis
(years)
mean7SD
Interval to
study (years)
mean7SD
HAA-IgA
(U/ml)
median
(range)
IgA (lg/ml)
median
(range)
HAA-IgA
(U/mg IgA)
median
(range)
UP/Cr
ratio
median
(range)
GFRa
(ml/min/
1.73 m2)
mean7SD
All patients 153 1.68 37.0714.5 4.976.9 1 731
(320–8 317)
3 943
(1 171–11 713)
445
(129–879)
0.60
(0.06–19.3)
57.0731.4
Male patients 96 39.8715.0 3.975.6 1 731
(373–8 317)
3 846
(1 171–11 713)
455
(129–834)
0.65
(0.06–5.35)
53.3730.8
Female patients 57 32.2727.8 6.578.4 1 707
(320–4 366)
4 213
(1 409–7 283)
428
(129–879)
0.54
(0.06–19.3)
63.1732.0
o8 weeks after biopsy 34 1.62 37.5714.1 0.0670.04 1 800
(508–4 366)
3 956
(1 418–6 327)
451
(160–879)
0.81
(0.07–4.36)
61.0739.0
45 years after biopsy 46 1.09 30.2711.9 13.377.0 1 974
(504–4 391)
4 440
(2 037–9 148)
425
(129–812)
0.19
(0.06–19.3)
60.7738.5
GFRo30 ml/min/1.73 m2 35 3.38 42.0715.5 4.577.2 1 856
(391–4 391)
3 584
(1 418–8 887)
525
(141–879)
1.25
(0.07–7.46)
17.976.8
GFR490 ml/min/1.73 m2 26 1.17 27.579.5 3.274.9 1 466
(320–3 579)
3 299
(1 409–7 422)
373
(170–710)
0.38
(0.06–2.53)
105.0716.3
Normal urinalysis 26 1.36 30.0710.3 11.878.9 2 030
(504–3 901)
4 571
(2 037–7 350)
417
(208–820)
0.09
(0.06–0.19)
45.5716.2
GFR, glomerular filtration rate; HAA, lectin from Helix aspersa; IgA, immunoglobulin A; UP/Cr ratio, urinary protein/creatinine ratio.
aEstimated GFR was calculated using the MDRD formula (53).
Table 2 | Diagnostic utility of serum IgA and HAA-IgA assays
Control Patients
Yes No Yes No Sensitivity Specificity Positive predictive Negative predictive
IgA 44 761mg/ml 15 135 50 103 0.327 (0.258, 0.405) 0.900 (0.842, 0.938) 0.769 (0.654, 0.855) 0.567 (0.504, 0.629)
HAA-IgA 41 076 U/ml 15 135 116 37 0.758 (0.685, 0.819) 0.900 (0.842, 0.938) 0.885 (0.820, 0.929) 0.785 (0.718, 0.840)
HAA-IgA 4394 U/mg IgA 15 135 94 59 0.614 (0.535, 0.685) 0.900 (0.842, 0.938) 0.785 (0.628, 0.756) 0.696 (0.628, 0.756)
HAA, lectin from Helix aspersa; IgA, immunoglobulin A.
The numbers in the brackets are the 95% confidence intervals.
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the cutoff point, 11 had a similarly increased value for HAA-
binding fraction of IgA.
Western blot analysis
To verify the ELISA data, selected serum samples from four
IgAN patients and two healthy controls representing a wide
range of HAA-IgA values were analyzed by Western blotting
for total and Gal-deficient IgA (see Materials and methods).
The band intensity was measured by densitometry and the
ratio of HAA-IgA to IgA heavy chain was calculated. This
value was plotted against HAA-binding fraction of IgA1
(U/mg IgA) determined by ELISA in the same sample. The
data in Figure 2 are representative for the IgAN patients and
healthy controls over the wide range of HAA-IgA values. The
results from the two assays showed good correlation
(r2¼ 0.818, P¼ 0.046).
Clinical and pathological associations
Serum HAA-IgA and IgA concentrations as well as values for
the HAA-binding fraction of IgA (U/mg IgA) are shown for
subgroups of patients in Table 2. There was no significant
difference based upon gender. The median level for 26
patients with a normal urinalysis at the time of study was
2 030 Units/ml (88% with an elevated level). Levels of HAA-
IgA for subjects with an estimated glomerular filtration rate
(GFR) X90 ml/min/1.73 m2 were similar to those of patients
with an estimated GFR o30 ml/min/1.73 m2. Furthermore,
the HAA-IgA levels did not significantly differ between
patients who had undergone renal biopsy within eight weeks
of the blood sampling and patients whose blood was
obtained more than five years after biopsy. Serum HAA-
IgA levels did not significantly correlate with urinary protein/
creatinine (UP/Cr) ratio (r¼0.128, P¼ 0.211), estimated
GFR (r¼0.147, P¼ 0.069), or interval since biopsy
(r¼ 0.0844, P¼ 0.300). Thus, the serum HAA-IgA level did
not appear to be an indicator of disease activity in our cohort
of Caucasian adults with IgAN.
Renal biopsies from 34 patients, who had blood obtained
within eight weeks of diagnostic biopsy, were graded
according to the Haas system27 by two investigators (WJC
and BAJ) blinded to the clinical and laboratory data. Levels of
HAA-IgA were above the cutoff value of healthy controls in
five of eight (63%) patients with subclass 1, 2, and 3
histological features and in 20 of 26 (77%) patients with
subclass 4 and 5 disease.
DISCUSSION
In this study, we developed a quantitative assay to measure
serum Gal-deficient IgA (HAA-IgA). Although the total IgA
correlated with the HAA-IgA levels, only the serum HAA-IgA
level differentiated IgAN patients from the healthy controls
with high sensitivity (Table 2). This finding may be explained
by a greater amount of Gal-deficient IgA recognized by
naturally occurring anti-glycan antibodies, resulting in
formation of CIC.10
In our ELISA, serum IgA was captured by a polyclonal IgA
heavy chain-specific antibody. As a result, both subclasses,
IgA1 that accounts for about 84% of serum IgA28,29 and
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Figure 1 | Serum levels of Gal-deficient IgA in IgAN patients and
healthy controls. (a) HAA-IgA level (U/ml, see Materials and
methods) in sera from IgAN patients and healthy controls.
(b) Receiver operating characteristic curve for HAA-IgA levels. Area
under the curve is 0.902. The arrows with numbers indicate key
points: (1) HAA-IgA serum level 1 076 U/ml; sensitivity 0.765,
specificity 0.900; (2) HAA-IgA serum level 1 702 U/ml; sensitivity 0.503,
specificity 0.993; and (3) HAA-IgA serum level 1 810 U/ml; sensitivity
0.444, specificity 1.000.
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Figure 2 | Reactivity of HAA with serum IgA in ELISA and Western
blot assays. ELISA data are expressed as HAA-IgA (U/mg IgA);
Western blot data are the ratios of heavy-chain band densities
for HAA-binding IgA and total IgA. Six samples with wide range of
HAA-IgA reactivities were used. The inset shows the two extremes:
a highly reactive sample and a modestly reactive sample.
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IgA2, are captured. However, only IgA1 has O-linked glycans
and, therefore, is the only IgA subclass that can bind to HAA,
a GalNAc-specific lectin. Consequently, the HAA-IgA assay is
a measure of serum Gal-deficient IgA1.
Mesangial IgA deposition is incidentally encountered in
asymptomatic individuals in frequencies that vary among
studies, ranging from 2 to 16%.30–34 For example, in a study
in Japan, biopsies from 510 newly procured living-donor
renal allografts taken at the time of transplantation showed
mesangial IgA deposition in 82 (16.1%) of them.33 By
contrast, in a study of necropsy examinations of 756 Finish
adults who had committed suicide or met with a violent
death, mesangial IgA deposits were found in 18 (2.4%) of the
individuals.32 However, these renal biopsies with IgA deposits
rarely showed any significant pathological changes by light
microscopy. Consequently, the clinical significance of these
observations is not clear, but many otherwise normal healthy
individuals may have mesangial deposits of IgA without
clinical manifestation of nephritis or pathological changes of
the glomeruli. It would have been interesting to have renal
biopsy data on our cohort of healthy controls and to assess
the frequency of IgA deposits with and without concurrent
renal pathology by light microscopy. However, this could not
have been carried out for ethical reasons.
Several groups of investigators have shown significantly
increased binding of GalNAc-specific lectins to serum IgA1
from patients with IgAN or Henoch–Scho¨nlein purpura
nephritis.10,11,23,35–40 Using HAA, Linossier et al.39 showed
increased binding for IgAN patients with normal thickness of
the glomerular basement membrane on electron microscopy.
Studies with other GalNAc-specific lectins, Vicia villosa
lectin23,38 and Glycine max lectin,40 showed increased serum
Gal-deficient IgA1 in patients with Henoch–Scho¨nlein
purpura nephritis and IgAN, respectively. However, these
results did not distinguish the patients from healthy controls;
thus, the test would not be adequate to diagnose either
disorder.
Several candidates for a serological diagnostic marker of
IgAN, such as increased levels of serum IgA or of IgA-
containing complexes with fibronectin, IgG, or C3, have been
previously examined.7–9,39–45 Although the serum IgA con-
centration is significantly elevated in about half of the
patients with IgAN,46,47 this parameter is not satisfactory as a
diagnostic test, as confirmed by our study (Table 2). Jennette
et al.42 found that 93% of 30 patients with IgAN or
Henoch–Scho¨nlein purpura nephritis had serum IgA-fibro-
nectin aggregates, compared with 7% of 30 controls. Later,
the same group performed a larger study with 63 adult and
25 pediatric subjects and found IgA-fibronectin aggregates in
only 40% of samples.43 Furthermore, just 48% of the patients
ever showed IgA-fibronectin aggregates, despite sampling on
more than one occasion.43 Czerkinsky et al.7 reported the
presence of IgA1- and IgG-containing CIC in 40% of 30
patients with IgAN and none in the 14 normal subjects.
Coppo et al.8,41 found IgA-CIC in 65% of IgAN patients
using a conglutinin-binding assay. The levels of IgA-CIC
correlated with clinical activity, as denoted by the magnitude
of microscopic hematuria or a history of macroscopic
hematuria. Mixed IgA1-IgG CICs were detected in 68% of
patients as reported by Schena et al.9 Activated C3 was
detected in 30–57% of patients with IgAN.44,45 To date, none
of these assays has been introduced as a diagnostic test.
Using a panel of 15 lectins, our group has examined the
reactivity of de-sialylated serum IgA1 from 10 patients with
IgAN and 10 healthy controls.11 All of the GalNAc-specific
lectins demonstrated higher reactivity with serum IgA1 from
the IgAN patients than with IgA1 from healthy controls;
however, the highest specificity was obtained with HAA.11
The specificity of many lectins (including those specific for
hinge-region O-linked glycans) may vary by the geographical
location of the source (animal or plant) and by the method of
preparation. It is thus possible that the HAA from the source
we chose had selectivity properties that were superior to
those of the other GalNAc-specific lectins we tested.11,26
These results prompted us to select HAA to use in our lectin
ELISA to measure the levels of Gal-deficient IgA1.
Gal-deficient IgA1 likely conveys nephritogenic properties
to the IgA1-CIC. Gal-deficient IgA1 has been isolated from
the immune deposits in the renal mesangium of patients with
IgAN.17,18 Furthermore, immune complexes with Gal-
deficient IgA1 stimulate mesangial cells in culture to
proliferate5,13,15,16,48 and secrete components of the extra-
cellular matrix and cytokines.49–51 Although the size and
biological activity of these CIC may be determined by various
factors, including the antigen to antibody ratio,13 the
aberrant glycosylation seems to play a central role in inducing
glomerular injury.52 Thus, measurement of Gal-deficient
IgA1 in serum samples may be of diagnostic significance,
despite the lack of an association between the serum HAA-
IgA level and disease severity, as assessed by histological
features, magnitude of proteinuria, or interval since diag-
nosis. The elevated serum HAA-IgA levels in patients during
a clinically quiescent phase many years after clinical onset
suggest that defective galactosylation may serve as a
biomarker for the disease.
Although Gal-deficiency of IgA1 O-linked glycans can be
analyzed by Western blotting, gas-liquid chromatography,
and mass spectrometry, these procedures are expensive and
cumbersome. In contrast, an ELISA is a relatively rapid,
inexpensive, and high-throughput assay with excellent
reproducibility. We anticipate that the HAA-IgA ELISA could
be easily adapted for the clinical laboratory. If the sensitivity
of this assay can be improved while maintaining its high
specificity, it may be developed into a noninvasive diagnostic
test for IgAN.
MATERIALS AND METHODS
Patients and healthy controls
The study included 153 Caucasian patients with IgAN who had
undergone biopsy for the evaluation of proteinuria, hematuria, or
renal dysfunction. Thirteen patients were younger than age 18 years
at the time of biopsy. All patients were older than age 18 at time of
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blood sampling for the study. Ninety-three were male, yielding a
male to female ratio of 1.68. Blood and urine samples were obtained
on one occasion. Mean age at biopsy was 37.0 years (range 10–75
years). The mean interval between the date of diagnosis by biopsy
and the date of blood sampling for this study was 4.9 years (range
0–29 years). Thirty-four (22%) patients were studied within eight
weeks of biopsy and 47 (31%) had blood drawn more than five years
after biopsy. Serum creatinine concentration, urinalysis and random
spot UP/Cr ratio were obtained at the time of study. Estimated GFR
was calculated using the Modification of Diet in Renal Disease
formula.53 Estimated GFR was X90 ml/min/1.73 m2 for 26 (17%)
patients,X60 but o90 ml/min/1.73 m2 for 40 (26%) patients, X30
but o60 ml/min/1.73 m2 for 52 (34%) patients, and o30 ml/min/
1.73 m2 for 35 (23%) patients.
The biopsy-proven diagnosis of IgAN was based upon the
demonstration by direct immunofluorescence of IgA as the
dominant or co-dominant Ig in a predominantly mesangial
distribution and the lack of clinical or serological evidence for
systemic lupus erythematosus, vasculitis, or Henoch–Scho¨nlein
purpura3 and the absence of X2þmesangial C1q deposition.54
The healthy controls consisted of 153 Caucasian residents of
Alabama, Kentucky, or Tennessee. All were at least 18 years of age
(range 18–80 years). The mean age was 27.071.9 years. The group
consisted of 74 males and 76 females. Serum creatinine, UP/Cr ratio
and blood pressure were measured for each healthy control.
Individuals with UP/Cr ratio 40.20 or estimated GFR o60 ml/
min/1.73 m2 were excluded. Estimated GFR was o90 ml/min/
1.73 m2 for 78 (50.9%) of the healthy controls.
The Institutional Review Boards at the University of Alabama at
Birmingham and the University of Tennessee Health Sciences Center
approved this study. Written informed consent was obtained from
all subjects.
Determination of serum IgA and Gal-deficient IgA by ELISA
For measurement of serum total and Gal-deficient IgA, high-
adsorption polystyrene 96-microwell plates (Nalge Nunc Interna-
tional, Rochester, NY, USA) were coated overnight with 3 mg/ml
F(ab0)2 fragment of goat IgG anti-human IgA (Jackson Immuno-
Research Labs., West Grove, PA, USA) in phosphate-buffered saline.
Coated plates were blocked with 1% bovine serum albumin (Sigma
Chemical Company, St Louis, MO, USA) in phosphate-buffered
saline-0.05%-Tween 20, and serial twofold dilutions of samples and
standards in blocking solution (in duplicate) were incubated
overnight at room temperature. The standard for IgA consisted of
a pool of normal human sera (Binding Site, Birmingham, UK),
previously calibrated for Ig isotype concentration by ELISA and
radial immunodiffusion. The bound IgA was detected by incubation
with biotin-labeled F(ab0)2 fragment of goat IgG anti-human IgA
(BioSource, Camarillo, CA, USA) for 3 h at 371C followed by 1 h
incubation with horseradish peroxidase-conjugated ExtrAvidin
(Sigma). For quantitation of Gal-deficient IgA, the standard
consisted of a polymeric Gal-deficient IgA1 isolated from serum
of a patient with IgA1 myeloma. This Ig has been previously shown
to mimic the aberrantly glycosylated IgA1 from IgAN patients.10 To
remove terminal sialic acid from O-linked GalNAc on IgA, the
samples and the IgA1 myeloma protein standard were incubated
with 100 ml (1 mU)/well neuraminidase (Roche Diagnostic Corp.,
Indianapolis, IN, USA) in 0.01 M acetate buffer pH 5 for 3 h at
371C.11 After washing, 100 ml biotin-labeled HAA, a GalNAc-specific
lectin, (1:500 dilution; Sigma) was added to each well. Following 3 h
incubation at 371C, the plates were washed and horseradish
peroxidase-ExtrAvidin (Sigma) was added and incubated for 1 h at
371C. For both IgA and Gal-deficient IgA, the wells were developed
with the peroxidase chromogenic substrate O-phenylenediamine-
H2O2 (Sigma). The color reaction was stopped with 1 M sulfuric acid
and the absorbance was measured at 490 nm with an EL312 Bio-
Kinetics microplate reader (Bio-Tek Instruments Inc., Winooski, VT,
USA). The amounts of total IgA and Gal-deficient IgA in the tested
samples were calculated with the DeltaSoft II program (BioMettalics
Inc., Princeton, NJ, USA) by interpolating the optical densities on
calibration curves, constructed using serum IgA and a Gal-deficient
IgA1 myeloma protein. As the standard IgA1 myeloma protein is not
entirely devoid of galactose, the expression of results in mg/ml does
not precisely reflect the concentration of Gal-deficient IgA1 in the
sera. Therefore, we expressed the results in U/ml. One unit of HAA-
IgA was defined as 1 mg of this standard. The results were also
normalized to total IgA and expressed in U/mg IgA.
Duplicate serum samples from 21 healthy controls were analyzed
to assess the degree of intra-assay variation. The results showed
excellent reproducibility (r¼ 0.970; Po0.0001). To verify the
accuracy of the ELISA measurements of total IgA level in serum,
five serum samples and the calibration serum were analyzed in the
clinical laboratory of the University of Alabama Hospital. The
differences in the measurements by ELISA and nephelometry ranged
between 2 and 17%, the mean difference was 975%.
Western blot analysis
Serum samples from six individuals (four IgAN patients and two
controls) representing a wide range of HAA-IgA values were
normalized for IgA content (1.0 or 0.1 mg IgA/well for blots to be
developed with HAA or anti-IgA, respectively), then reduced with
5% b-mercaptoethanol, and electrophoreticaly separated on a
4–15% gradient sodium dodecyl sulfate-polyacrylamide gel (Bio-
Rad, Hercules, CA, USA). The gels were then electroblotted to
polyvinylidine difluoride membrane (0.45 mm, Millipore, Billerica,
MA, USA). After the transfer, polyvinylidine difluoride membranes
were blocked with SuperBlock buffer (Pierce, Rockford, IL, USA)
containing 0.05% Tween 20, washed and treated for 3 h at 371C with
10 mU/ml neuraminidase (Roche). Membranes were then washed
and incubated overnight at 41C with 1:500 dilution biotin-labeled
HAA (Sigma) in blocking buffer. To detect the heavy chain of IgA, a
duplicate membrane was incubated overnight at 41C with
biotinylated goat F(ab’)2 IgG anti-human IgA (Biosource). The
biotin-labeled probes bound to IgA were detected, after addition of
streptavidin-horseradish peroxidase conjugate, with SuperSignal
West Pico Solution (Pierce). The positive bands were visualized
using X-ray film (Kodak, Rochester, NY, USA) and the films were
analyzed by densitometry to calculate the ratios of HAA-IgA to
a-chain.
Statistical analysis
Wilcoxon rank sum test was used to compare subject and control
groups for serum concentrations of IgA, HAA-IgA levels, and relative
HAA-binding to IgA. The 90th percentile for healthy controls was the
cutoff point for calculation of sensitivity and specificity. The receiver
operating characteristic curve for HAA-IgA levels in patients and
controls was constructed using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego, CA, USA). The Spearman
correlation coefficients were used to assess the relationship between
HAA-IgA levels and UP/Cr ratio, estimated GFR and the interval since
diagnosis by biopsy. SAS 9.1 (SAS Institute, Cary, NC, USA) was used
for descriptive statistics and calculation of correlation coefficients.
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